Search research articles
Contact Us
Filters
Showing results (41-50 of 107) with videos related to
Page
of 11
Sort By:
Clinical and Translational Science
|
March 5, 2026
Clinical Evaluation of Drug-Drug Interactions With Aficamten
Neha Maharao, Donghong Xu, Punag Divanji, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
March 22, 2014
Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study
Emma C Scott, Stephen B Heitner, William Dibb, et al.
International Journal of Cardiology
|
April 28, 2025
Reply to: Correction to external evaluation of a commercial artificial intelligence-augmented digital auscultation platform in valvular heart disease detection using echocardiography as reference standard
Valentina Roquemen-Echeverri, Peter G Jacobs, Evan F Shalen, et al.
ESC Heart Failure
|
October 28, 2021
Perioperative Amiodarone to Prevent Atrial fibrillation after Septal Myectomy in obstrUctive hypeRtroPHic cardiomyopathy
Evan F Shalen, Stephen B Heitner, Lana Al-Rashdan, et al.
International Journal of Cardiology
|
October 21, 2024
External evaluation of a commercial artificial intelligence-augmented digital auscultation platform in valvular heart disease detection using echocardiography as reference standard
Valentina Roquemen-Echeverri, Peter G Jacobs, Evan F Shalen, et al.
JACC. Heart Failure
|
October 22, 2025
Efficacy and Safety of Omecamtiv Mecarbil in Heart Failure With Reduced Ejection Fraction According to Age: The GALACTIC-HF Trial
Henri Lu, Brian L Claggett, G Michael Felker, et al.
JAMA Cardiology
|
January 28, 2026
One-Year Outcomes in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction Prescribed Quadruple Medical Therapy at Discharge
Stephen J Greene, Haolin Xu, Karen Chiswell, et al.
The American Journal of Cardiology
|
September 4, 2023
Potential Applicability of Omecamtiv Mecarbil to Patients Hospitalized for Worsening Heart Failure
Josephine Harrington, Jie-Lena Sun, Gregg C Fonarow, et al.
European Journal of Heart Failure
|
July 18, 2024
Safety and efficacy of aficamten in patients with non-obstructive hypertrophic cardiomyopathy: A 36-week analysis from FOREST-HCM
Ahmad Masri, Roberto Barriales-Villa, Perry Elliott, et al.
European Journal of Heart Failure
|
March 2, 2026
Effect of the cardiac myosin activator omecamtiv mecarbil on ventricular arrhythmias, cardiac arrest, and sudden death in heart failure with reduced ejection fraction: the GALACTIC-HF trial
Alberto Foà, Muthiah Vaduganathan, Brian L Claggett, et al.
Page
of 11
Search research articles
Search
Showing results (41-50 of 107) with videos related to
Sort By:
Page
of 11
Clinical and Translational Science
|
March 5, 2026
Clinical Evaluation of Drug-Drug Interactions With Aficamten
Neha Maharao, Donghong Xu, Punag Divanji, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
March 22, 2014
Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study
Emma C Scott, Stephen B Heitner, William Dibb, et al.
International Journal of Cardiology
|
April 28, 2025
Reply to: Correction to external evaluation of a commercial artificial intelligence-augmented digital auscultation platform in valvular heart disease detection using echocardiography as reference standard
Valentina Roquemen-Echeverri, Peter G Jacobs, Evan F Shalen, et al.
ESC Heart Failure
|
October 28, 2021
Perioperative Amiodarone to Prevent Atrial fibrillation after Septal Myectomy in obstrUctive hypeRtroPHic cardiomyopathy
Evan F Shalen, Stephen B Heitner, Lana Al-Rashdan, et al.
International Journal of Cardiology
|
October 21, 2024
External evaluation of a commercial artificial intelligence-augmented digital auscultation platform in valvular heart disease detection using echocardiography as reference standard
Valentina Roquemen-Echeverri, Peter G Jacobs, Evan F Shalen, et al.
JACC. Heart Failure
|
October 22, 2025
Efficacy and Safety of Omecamtiv Mecarbil in Heart Failure With Reduced Ejection Fraction According to Age: The GALACTIC-HF Trial
Henri Lu, Brian L Claggett, G Michael Felker, et al.
JAMA Cardiology
|
January 28, 2026
One-Year Outcomes in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction Prescribed Quadruple Medical Therapy at Discharge
Stephen J Greene, Haolin Xu, Karen Chiswell, et al.
The American Journal of Cardiology
|
September 4, 2023
Potential Applicability of Omecamtiv Mecarbil to Patients Hospitalized for Worsening Heart Failure
Josephine Harrington, Jie-Lena Sun, Gregg C Fonarow, et al.
European Journal of Heart Failure
|
July 18, 2024
Safety and efficacy of aficamten in patients with non-obstructive hypertrophic cardiomyopathy: A 36-week analysis from FOREST-HCM
Ahmad Masri, Roberto Barriales-Villa, Perry Elliott, et al.
European Journal of Heart Failure
|
March 2, 2026
Effect of the cardiac myosin activator omecamtiv mecarbil on ventricular arrhythmias, cardiac arrest, and sudden death in heart failure with reduced ejection fraction: the GALACTIC-HF trial
Alberto Foà, Muthiah Vaduganathan, Brian L Claggett, et al.
Page
of 11